Navigation Links
Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease
Date:6/11/2009

About Dimebon

Dimebon is an investigational compound currently in Phase 3 development for the treatment of Alzheimer's disease and in clinical development for Huntington disease. In preclinical models of Alzheimer's disease and Huntington disease explored thus far, dimebon has been shown to inhibit brain cell death, potentially by stabilizing and improving mitochondrial function in a way that prevents neuron death and dysfunction. The dimebon mechanism is thought to be distinct from that of currently available Alzheimer's disease medications.

In addition to CONNECTION, dimebon is being studied in the 12-month Phase 3 CONCERT trial, which is evaluating the efficacy of dimebon when added to ongoing treatment with donepezil (Aricept(R)) in patients with mild-to-moderate Alzheimer's disease, and in a Phase 3 safety study. Two Phase 3 studies in moderate-to-severe Alzheimer's disease are also planned to start this year.

In Huntington disease, a Phase 2 study has been completed. Medivation and Pfizer expect to initiate a Phase 3 trial this year to evaluate the potential benefits of dimebon on cognition in patients with Huntington disease.

About Alzheimer's Disease

Alzheimer's disease is a progressive degenerative brain disorder that gradually destroys a person's memory and ability to learn, reason, make judgments, communicate and carry out daily activities. As the disease progresses, patients may experience changes in personality and behavior, such as anxiety, suspiciousness or agitation, as well as delusions or hallucinations.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medivation Announces Pricing of Public Offering
2. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
3. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
4. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
5. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
6. Medivation Presents New Data on Dimebons Novel Mechanism of Action
7. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
8. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
9. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
10. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
11. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... ... needs and expertly narrows down the product choices to a manageable shortlist of ... down the list to models that fit best with the customer’s industry and ...
(Date:8/26/2015)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... for the detection of foodborne pathogens, today announced that ... & Company Emerging Growth Conference on September 2 at ... New York Marriott Marquis. A live ... investor relations section of Roka Bioscience,s website at ...
(Date:8/26/2015)... 26, 2015 Israel Proves Its Place in ... st place  Wayerz comes in 5 th ... by venture capital fund JVP, with Chinese consulting firm ... China , Israel , ... Impressive achievement for the Israeli representatives in the final round ...
(Date:8/26/2015)... ... August 26, 2015 , ... The 2015 Epigenomics & ... stem cell technology start-up company Asymmetrex to share the first report on ... a new biomarker for counting adult tissue stem cells. , With a name like ...
Breaking Biology Technology:METTLER TOLEDO Updates Online Scale Selection Tool 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4
... No Child Should Die of Diabetes, BRUSSELS, October ... it is bringing together key opinion,leaders to push for ... diabetes in developing countries without access to care., ... in the,Developing World, will be held on Saturday, October ...
... Therapeutics is,presenting new data today representing an ... to enhance outcomes in patients,suffering from lower ... "Local Catheter-Directed Elastase Therapy: A Novel,Approach to ... at the 20th,annual Transcatheter Cardiovascular Therapeutics (TCT) ...
... risk of basal,cell carcinoma, and are integrated into ... Oct. 13 Scientists at,deCODE genetics (Nasdaq: ... of two single-letter variations in the human genome ... the most common cancer among,people of European ancestry. ...
Cached Biology Technology:International Diabetes Federation Calls for Global Action to Keep All Children With Diabetes Alive 2International Diabetes Federation Calls for Global Action to Keep All Children With Diabetes Alive 3Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008 2deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer 2deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer 3deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer 4
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics ... of human interface solutions, today announced collaboration with ... on Windows 10. Microsoft leveraged Synaptics, deep expertise ... operating system. Through stringent testing, ... fully certified with Microsoft,s Precision TouchPad (PTP) specification ...
(Date:8/5/2015)... 5, 2015 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... facial recognition is forecast to reach US$ 2,671.8 Mn ... for surveillance systems by civil and government agencies. This ... and terrorist activities across the globe that would elevate ...
(Date:8/4/2015)... 04, 2015 ... announced the addition of the "Digital ... Service), Sub-Segment (Computer Forensics, Network Forensics, Mobile ... Service, Vertical and Region - Global Forecast ... By Component (Hardware, Software, and ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... bumble bees are at risk, other bee species in ... despite expanding human populations and changing land use. Led ... from the American Museum of Natural History and nine ... at protecting native bee species and the important pollinator ...
... brain adds new cells during puberty to help navigate the ... report in the current issue of the Proceedings of ... think the brain cells you,re born with are all you ... in adults, conventional wisdom held that such growth was limited ...
... an additional 100.000 Euros in financial support , ... the financial support through the execution of the business ... the Building Global Innovators & continued financial support by ... Building Global Innovators Venture Competition. The seamless low-cost vehicle-based ...
Cached Biology News:New research confirms plight of bumble bees, persistence of other bees in Northeast 2Brain adds cells in puberty to navigate adult world 2Veniam is the winner of the major Portuguese Venture Competition 'Builidng Global Innovators' 2Veniam is the winner of the major Portuguese Venture Competition 'Builidng Global Innovators' 3Veniam is the winner of the major Portuguese Venture Competition 'Builidng Global Innovators' 4
... detection of apoptosis and mitochondrial membrane potential. ... early indication of the initiation of cellular ... a collapse in the electrochemical gradient across ... change in the membrane potential (YD). Loss ...
... CYCLES. An assay kit designed to detect ... PARP is an enzyme implicated in DNA ... is cleaved by caspase-3. Cleavage of PARP ... kDa is a hallmark of apoptosis. Each ...
... the DH-2000, but comes with a shutter (controlled ... 5 Hz) The DH-2000 Deuterium ... of deuterium and tungsten halogen light sources in ... produces a powerful, stable output from 215-200 nm. ...
... The MSD Security ChemStation ... GC/MS software application for ... quantification, library searching and ... aspects of data security, ...
Biology Products: